Charles River Laboratories, International Inc. has received regulatory approval - in the form of Good Manufacturing Practice (GMP) certification - to commercially produce allogeneic cell therapy drug products for distribution in Europe, from the European...
Millipore Sigma has launched its VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform: meaning the CDMO can now provide a full viral vector manufacturing offering including AAV, Lentiviral, CDMO, CTO, and process development.
GreenLight Biosciences and Samsung Biologics have completed the first commercial-scale engineering run under the companies’ mRNA production partnership: ahead of a COVID-19 vaccine booster clinical trial due to start later this year.
CDMO WuXi Biologics will invest $1.4bn in a 10 year investment plan to expand its research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore.
Umoja Biopharma and TreeFrog Therapeutics have formed an alliance to address challenges facing ex vivo allogeneic therapies in immuno-oncology, including issues scaling up production to reach all patients.
Eli Lilly and Company plans to expand its manufacturing footprint in Indiana by investing $2.1bn in two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County.
Cytiva is opening a new 7,400m² manufacturing facility in Grens, Switzerland this month: which will serve as a center of excellence for the company’s cell and gene therapy business as well as a being a base for European customer training programs.
CDMO Matica Bio has opened a new 45,000-square-foot facility dedicated to the production of viral vectors and cell-based products used in cell and gene therapies, vaccines, oncolytic therapies and other genetic medicines.
Quay Pharma, a contract development and manufacturing organization (CDMO), has signed a contract with drug development specialist, Liveome, in relation to the Korean firm’s live biotherapeutic program.
US company Catalent is acquiring the UK’s Vaccine Manufacturing and Innovation Centre in Harwell: a facility which had been planned to support COVID-19 and wider vaccine production and which is still under construction.
The US Food and Drug Administration (FDA) has granted commercial licensure approval for Novartis’ Durham, N.C. site, a multi-product gene therapy manufacturing facility, which will start producing Zolgensma immediately.
CytoImmune Therapeutics, a clinical-stage immunotherapy company developing a novel class of engineered natural killer (NK) cell-based cancer therapies, has announced the opening of its clinical cell manufacturing facility in Toa Baja, Puerto Rico.
The Cell and Gene Therapy Catapult (CGT Catapult) has today published the ‘National Cell and Gene Therapy Vision for the UK’, a document outlining recommendations for a national strategy for the adoption of cell and gene therapies.
Moderna has finalized a strategic partnership with the Australian government to build an mRNA manufacturing facility in Melbourne: which is expected to produce up to 100 million mRNA respiratory vaccine doses annually.
A California based biotech has tripled its capacity to manufacture GMP grade induced pluripotent stem cells (iPSC) space through the expansion of its contract development and manufacturing (CDMO) facility.
Nutcracker Therapeutics, a biotech developing RNA therapeutics using its proprietary biochip-based manufacturing platform, has raised $167m in Series C financing: allowing it to expand and advance its pipeline of mRNA medicines for cancer and further...